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Annual Report
Australian Group on Antimicrobial Resistance 
(AGAR) Australian Staphylococcus aureus 
Sepsis Outcome Programme (ASSOP) 
Annual Report 2017
Geoffrey W Coombs, Denise A Daley, Yung Thin Lee, Stanley Pang on behalf of the Australian 
Group on Antimicrobial Resistance
Abstract
From 1 January to 31 December 2017, 36 institutions around Australia participated in the Australian 
Staphylococcus aureus Sepsis Outcome Programme (ASSOP). The aim of ASSOP 2017 was to deter-
mine the proportion of Staphylococcus aureus bacteraemia (SAB) isolates in Australia that are anti-
microbial resistant, with particular emphasis on susceptibility to methicillin and to characterise the 
molecular epidemiology of the methicillin-resistant isolates. A total of 2,515 S. aureus bacteraemia 
episodes were reported, of which 77% were community-onset. Approximately one in five S. aureus 
(19.0%) were methicillin resistant. The 30-day all-cause mortality associated with methicillin-resistant 
SAB was 18.7% which was significantly higher than the 14.0% mortality associated with methicillin-
susceptible SAB. With the exception of the β-lactams and erythromycin, antimicrobial resistance in 
methicillin-susceptible S. aureus was rare. However in addition to the β-lactams approximately 42% of 
methicillin-resistant S. aureus (MRSA) were resistant to erythromycin and ciprofloxacin and approxi-
mately 14% resistant to co-trimoxazole, tetracycline and gentamicin. When applying the EUCAST 
breakpoints teicoplanin resistance was detected in five S. aureus isolates. Resistance was not detected 
for vancomycin and linezolid. Resistance to non-beta-lactam antimicrobials was largely attributable 
to two healthcare-associated MRSA clones: ST22-IV [2B] (EMRSA-15) and ST239-III [3A] (Aus-2/3 
EMRSA). ST22-IV [2B] (EMRSA-15) is the predominant healthcare-associated clone in Australia. 
Seventy-five percent of methicillin-resistant SAB were due to community-associated clones. Although 
polyclonal approximately 74% of community-associated clones were characterised as ST93-IV [2B] 
(Queensland CA-MRSA), ST5-IV [2B], ST45-VT [5C2&5] and ST1-IV [2B]. CA-MRSA, in particular 
the ST45-VT [5C2&5] clone has acquired multiple antimicrobial resistance determinants including 
ciprofloxacin, erythromycin, clindamycin, gentamicin and tetracycline. ST45-VT [5C2&5] accounted 
for 12.8% of CA-MRSA. As CA-MRSA is well established in the Australian community it is important 
antimicrobial resistance patterns in community- and healthcare-associated SAB is monitored as this 
information will guide therapeutic practices in treating S. aureus sepsis.
Keywords: Australian Group on Antimicrobial Resistance (AGAR); antimicrobial resistance surveil-
lance; Staphylococcus aureus, methicillin-susceptible Staphylococcus aureus (MSSA), methicillin-
resistant Staphylococcus aureus (MRSA), bacteraemia
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Background
Globally Staphylococcus aureus is one of the 
most frequent causes of hospital-acquired and 
community-acquired blood stream infections.1 
Although there are a wide variety of manifesta-
tions of serious invasive infection caused by S. 
aureus, in the great majority of these cases the 
organism can be detected in blood cultures. 
Therefore, S. aureus bacteraemia (SAB) is con-
sidered a very useful marker for serious invasive 
infection.2
Although prolonged antimicrobial therapy and 
prompt source control are used to treat SAB,3 
mortality ranges from as low as 2.5% to as high 
as 40%.4–6 Mortality rates, however, are known 
to vary significantly with patient age, clinical 
manifestation, comorbidities and methicil-
lin resistance.7,8 A prospective study of SAB 
conducted in 27 laboratories in Australia and 
New Zealand found a 30-day all-cause mortal-
ity of 20.6%.9 On univariate analysis increased 
mortality was significantly associated with older 
age, European ethnicity, methicillin resist-
ance, infections not originating from a medical 
device, sepsis syndrome, pneumonia/empyema 
and treatment with a glycopeptide or other non-
β-lactam antibiotic.
The Australian Group on Antimicrobial 
Resistance (AGAR), a network of laborato-
ries located across Australia, commenced 
surveillance of antimicrobial resistance in S. 
aureus in 1986.10 In 2013 AGAR commenced 
the Australian Staphylococcus aureus Sepsis 
Outcome Programme (ASSOP).11 The primary 
objective of ASSOP 2017 was to determine 
the proportion of SAB isolates demonstrat-
ing antimicrobial resistance with particular 
emphasis on:
1. Assessing susceptibility to methicillin
2. Molecular epidemiology of methicillin-re-
sistant S. aureus (MRSA).
Methodology
Participants
Thirty-six laboratories from all eight Australian 
states and mainland territories.
Collection Period
From 1 January to 31 December 2017, the 36 
laboratories collected all S. aureus isolated from 
blood cultures. S. aureus with the same anti-
microbial susceptibility profiles isolated from a 
patient’s blood culture within 14 days of the first 
positive culture were excluded. A new S. aureus 
sepsis episode in the same patient was recorded 
if it was identified by a culture of blood collected 
more than 14 days after the last positive culture. 
Data were collected on age, sex, date of admis-
sion and discharge (if admitted), and mortality at 
30 days from date of first positive blood culture. 
To avoid interpretive bias, no attempt was made 
to assign attributable mortality. Each episode of 
bacteraemia was designated healthcare onset if 
the first positive blood culture(s) in an episode 
were collected >48 hours after admission.
Laboratory Testing
Participating laboratories performed antimi-
crobial susceptibility testing using the Vitek2® 
(bioMérieux, France) or the Phoenix™ (Becton 
Dickinson, USA) automated microbiology sys-
tems according to the manufacturer’s instruc-
tions. S. aureus was identified by morphology 
and positive results of at least one of the following 
tests: Vitek MS® (bioMérieux, France), matrix-
assisted laser desorption ionization (MALDI) 
biotyper (Bruker Daltonics, Germany), slide 
coagulase, tube coagulase, appropriate growth 
on chromogenic agar and demonstration of 
deoxyribonuclease production. Additional tests 
such as fermentation of mannitol, growth on 
mannitol-salt agar or polymerase chain reaction 
(PCR) for the presence of the nuc gene may have 
been performed for confirmation.
Minimum inhibitory concentration (MIC) data 
and isolates were referred to the Antimicrobial 
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Resistance and Infectious Diseases (AMRID) 
Research Laboratory at Murdoch University. 
Clinical and Laboratory Standards Institute 
(CLSI)12 and European Committee on 
Antimicrobial Susceptibility Testing 
(EUCAST)13 breakpoints were utilised for inter-
pretation. Isolates with a resistant or an interme-
diate category were classified as non-susceptible. 
Linezolid and daptomycin non-susceptible 
isolates were retested by Etest® (bioMérieux) 
using the Mueller-Hinton agar recommended 
by the manufacturer. S. aureus ATCC 29213 was 
used as the control strain. High level mupirocin 
resistance was determined by the Phoenix™ or 
by using a mupirocin 200 μg disk according to 
CLSI guidelines on all isolates with a mupirocin 
MIC >8 mg/L by Vitek2®. Multi-resistance was 
defined as resistance to three or more of the 
following non-β-lactam antimicrobials: vanco-
mycin, teicoplanin, erythromycin/clindamycin, 
tetracycline, ciprofloxacin, gentamicin, co-
trimoxazole, fusidic acid, rifampicin, high level 
mupirocin, and linezolid.
Molecular testing was performed by whole 
genome sequencing (WGS) using the MiSeq plat-
form (Illumina, San Diego, USA). Sequencing 
results were analysed using the Nullarbor 
pipeline.14 The online spa typing tool described 
by Bartels et al.15 was applied to determine spa 
types. SCCmec elements were identified using 
SCCmec sequences described by Monecke et al.16
Chi-square tests for comparison of two propor-
tions and calculation of 95% confidence inter-
vals (95%CI) were performed using MedCalc 
for Windows, version 12.7 (MedCalc Software, 
Ostend Belgium).
Approval to conduct the prospective data collec-
tion was given by the research ethics committee 
associated with each participating laboratory.
Results
From 1 January to 31 December 2017, a total of 
2,515 unique episodes of S. aureus bacteraemia 
were identified. A significant difference (p<0.001) 
was seen in patient sex with 66.5% (1,673) being 
male (95% CI 64.6–68.3). The average age of 
patients was 57 years ranging from 0–101 years 
with a median age of 62 years. Overall 77.0% 
(1,936/2,515) of episodes were community 
onset (95% CI 75.3% – 78.6%). All-cause mor-
tality at 30 days was 14.8% (95% CI 13.3–16.4). 
Methicillin-resistant SAB mortality was 18.7% 
(95% CI 14.8–23.1) which was significantly 
higher than for methicillin-susceptible SAB 
mortality (14.0%, 95% CI 12.3–15.8) (p=0.03).
Methicillin-Susceptible Staphylococcus 
aureus (MSSA) Antimicrobial 
Susceptibility
Overall 81.0% (2,037) of the 2,515 isolates were 
methicillin susceptible of which 77.2% (1,572) 
were penicillin resistant (MIC >0.12 mg/L). 
However as β-lactamase was detected in 62 phe-
notypically penicillin susceptible isolates, 80.3% 
of MSSA were considered penicillin resistant. 
Apart from erythromycin non-susceptibility 
(12.4%), resistance to the non-β-lactam antimi-
crobials amongst MSSA was rare, ranging from 
0% to 3.3% (Table 1). There were ten isolates 
reported by Vitek2® as non-susceptible to dapto-
mycin (MIC >1.0 mg/L). By Etest®, six of the iso-
lates were considered susceptible (MICs 0.38–1.0 
mg/L). Four isolates had Etest® MICs of 1.5–2.0 
and therefore were considered non-susceptible. 
Using WGS, daptomycin non-susceptibility in 
two isolates was due to single point mutations 
in the mprF gene: mprF-I420T and mprF-L826I. 
No known single point mutations were identi-
fied in two isolates. By Vitek2®, two isolates were 
linezolid resistant (MIC >4 mg/L). However 
by Etest®, the isolates had MIC ≤4 mg/L (3.0 
mg/L) and were therefore considered linezolid 
susceptible. When using the EUCAST resist-
ant breakpoint of >2 mg/L, four  isolates were 
teicoplanin resistant (MIC = 4 mg/L). However, 
using the CLSI resistant breakpoint of >8 mg/L, 
the isolates were classified as susceptible. All 
MSSA were vancomycin susceptible. Thirty 
(1.5%) of 2,035 isolates had high-level mupirocin 
resistance of which 21 isolates were referred 
from Queensland. Seventeen of the thirty 
mupirocin resistant MSSA were also resistant to 
fusidic acid. Inducible resistance to clindamycin 
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was determined by the Vitek2® susceptibility 
system. Of the 2,218 isolates tested, 14% (311) 
were erythromycin non-susceptible / clindamycin 
intermediate / susceptible (CLSI breakpoints) 
of which 85.2% (265) were classified as hav-
ing inducible clindamycin resistance. Multi-
resistance was uncommon in MSSA (0.5%, 
9/1,983).
There were no significant differences in antimi-
crobial interpretation when CLSI or EUCAST 
non susceptibility breakpoints were utilised 
(p>0.05).
MRSA Antimicrobial Susceptibility
The proportion of S. aureus that were MRSA 
was 19.0% (95% CI 17.5–20.6). Of the 478 MRSA 
identified 418 were cefoxitin screen positive 
by Vitek2® and 58 had a cefoxitin MIC >4 by 
Phoenix™. Two isolates were cefoxitin screen 
Table 1: The number and proportion of methicillin-susceptible Staphylococcus aureus (MSSA) 
isolates non-susceptible to penicillin and the non-β-lactam antimicrobials, Australia, 2017
Antimicrobial Number Tested Breakpoint (mg/L)
Non-Susceptible
n %
Penicillin 2,035 >0.12a 1,634 80.3
Vancomycin 2,035 >2a 0 0.0
Teicoplanin 2,034
>8b 0 0.0
>2c 4 0.2
Rifampicin 1,991
>1b 8 0.4
>0.5c 9 0.5
Fusidic Acid 2,035 >1c 65 3.2
Gentamicin 2,034
>4b 15 1.1
>1c 23 0.7
Erythromycin 2,035
>0.5b 253 12.4
>2c 216 10.6
Clindamycin 2,034 >0.5a 32 1.6
Tetracycline/
Doxycycline 2,029
>4b 65 3.2
>2c 66 3.3
Co-trimoxazole 2,033
>2/38b 44 2.2
>4/76c 39 1.9
Ciprofloxacin 2,030 >1a 53 2.6
Nitrofurantoin 1,922
>32b 4 0.2
>64c 0 0
Daptomycin 2,036 >1a 4 0.2
Linezolid 2,037 >4a 0 0
a CLSI and EUCAST non-susceptible breakpoint
b CLSI non-susceptible breakpoint
c EUCAST non-susceptible breakpoint
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negative but harboured the mecA gene. All 478 
MRSA isolates were phenotypically penicillin 
resistant. Amongst the MRSA isolates, non-sus-
ceptibility to non-β-lactam antimicrobials was 
common except for nitrofurantoin, rifampicin 
and fusidic acid where resistance ranged from 
1.1% to 4.0% (Table 2). There were three isolates 
reported by Vitek2® as non-susceptible to dap-
tomycin (MIC >1.0 mg/L). By Etest®, one of the 
isolates was considered susceptible (MIC 0.38 
mg/L). The remaining two isolates had Etest® 
MICs of 2.0 mg/L and therefore were considered 
non-susceptible. Using WGS, daptomycin non-
susceptibility was due to single point mutations 
in the mprF gene: mprF-L826F and mprF-P314S.
When using the EUCAST resistant breakpoint 
of >2 mg/L, one isolate was teicoplanin resist-
ant (MIC = 8 mg/L). However, using the CLSI 
resistant breakpoint of >8 mg/L, the isolate was 
classified as susceptible. Ten (2.1%) of 478 MRSA 
isolates tested had high-level mupirocin resist-
ance, of which six were from Queensland.
Inducible resistance to clindamycin was deter-
mined by the Vitek2® susceptibility system. Of 
the 415 isolates tested by Vitek2®, 27.7% (115) 
were erythromycin non-susceptible / clindamycin 
intermediate / susceptible (CLSI and EUCAST 
breakpoints) of which 81.7% (94) were classified 
as having inducible clindamycin resistance.
Multi-resistance was seen in 31.3% of MRSA.
There were no significant differences in inter-
pretation for any drug when CLSI or EUCAST 
non-susceptibility breakpoints were utilised.
MRSA Molecular Epidemiology
WGS was performed on 96.7% (462/478) of the 
MRSA. Based on molecular typing, 25.5% (118) 
and 74.5% (344) of isolates were identified as 
healthcare-associated MRSA (HA-MRSA) and 
community-associated MRSA (CA-MRSA) 
clones respectively (Table 3).
Healthcare-associated methicillin-
resistant Staphylococcus aureus
For the 118 HA-MRSA isolates, 45.8% (54) were 
epidemiologically classified as hospital-onset 
and 54.2% (64) were classified as community-
onset. Three HA-MRSA clones were identified: 
90 isolates of ST22-IV [2B] (EMRSA-15) (19.5% 
of MRSA typed and 3.6% of S. aureus); 25 isolates 
of ST239-III [3A] (Aus -2/3 EMRSA) (5.4% and 
1.0%) and three isolates of ST5-II [2A] (USA100/
New York Japan) (0.6% and 0.1%).
ST22-IV [2B] (EMRSA-15) was the dominant 
HA-MRSA clone in Australia accounting for 
76% of HA-MRSA ranging from 33.3% in the 
Northern Territory to 100% in Western Australia 
and the Australian Capital Territory (Table 4). 
ST22-IV [2B] (EMRSA-15) is PVL negative and 
using CLSI breakpoints 96.7% and 46.7% were 
ciprofloxacin and erythromycin non-susceptible 
respectively. Overall 42.2% of ST22-IV were 
hospital-onset.
ST239-III [3A] (Aus-2/3 EMRSA) accounted for 
21.2% of HA-MRSA ranging from 0% in Western 
Australia and the Australian Capital Territory 
to 66.7% in the Northern Territory (Table 4). 
PVL negative ST239-III [3A] (Aus-2/3 EMRSA) 
were typically resistant to erythromycin (100%), 
co-trimoxazole (92.0%), ciprofloxacin (96.0%), 
gentamicin (100%), tetracycline (72.0%) and 
clindamycin (60.0%). Overall 68.08% of ST239-
III were hospital-onset.
The three isolates of ST5-II [2A] (USA100/New 
York Japan) were identified in Queensland and 
New South Wales (Table 4) and were resistant 
to the β-lactams. Two of the three isolates were 
additionally resistant to fusidic acid. All were 
PVL negative.
Community-associated methicillin-
resistant Staphylococcus aureus
For the 344 CA-MRSA isolates, 24.4% (84) 
of episodes were epidemiologically classified 
as hospital-onset and 75.6% (260) classified 
as community-onset. Based on the multi 
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Table 2: The number and proportion of methicillin-resistant Staphylococcus aureus (MRSA) 
isolates non-susceptible to penicillin and the non-β-lactam antimicrobials, Australia, 2017
Antimicrobial Number Tested Breakpoint (mg/L)
Non-Susceptible (%)
n %
Penicillin 478 >0.12a 478 100
Vancomycin 478 >2a 0 0
Teicoplanin 477
>8b 0 0
>2c 1 0.2
Rifampicin 475
>1b 9 1.9
>0.5c 9 1.9
Fusidic Acid 477 >1c 19 4.0
Gentamicin 477
>4b 73 15.3
>1c 79 16.6
Erythromycin 477
>0.5b 199 41.7
>2c 197 41.3
Clindamycin 475 >0.5a 67 14.1
Tetracycline/
Doxycycline 476
>4b 67 14.1
>2c 74 15.5
Co-trimoxazole 475
>2/38b 61 12.8
>4/76c 57 12.0
Ciprofloxacin 476 >1a 198 41.6
Nitrofurantoin 450
>32b 5 1.1
>64c 0 0
Daptomycin 478 >1a 2 0.4
Linezolid 478 >4a 0 0
a CLSI and EUCAST non-susceptible breakpoint
b CLSI non-susceptible breakpoint
c EUCAST non-susceptible breakpoint
locus sequence type and the SCCmec type, 40 
CA-MRSA clones were identified (Table 3). 
Overall, 71.5% of CA-MRSA were classified into 
five clones each having more than ten isolates: 
ST93-IV [2B] (Queensland CA-MRSA) (24.5% 
of MRSA typed and 4.5% of S. aureus); ST45-VT 
(9.4% and 1.7%); ST5-IV (8.4% and 1.6%); ST1-IV 
(7.4% and 1.4%); and ST78-IV (3.5% and 0.6%).
ST93-IV [2B] (Queensland CA-MRSA) 
accounted for 32.8% of CA-MRSA ranging 
from 0% in Tasmania to 74.4% in the Northern 
Territory (Table 5). Typically PVL positive, 
76.5% (78/102) of ST93-IV [2B] (Queensland 
CA-MRSA) were resistant to the β-lactams 
only or additionally resistant to erythromycin 
(16.8%, 19/113) or erythromycin and clinda-
mycin (3.5%, 4/113). There were two isolates 
resistant to gentamicin and one isolate resistant 
to ciprofloxacin. Overall 85.0% of ST93-IV were 
community-onset.
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ST45-VT accounted for 12.8% of CA-MRSA and 
was isolated primarily in New South Wales and 
Victoria (Table 5). All isolates were PVL nega-
tive and were resistant to the β-lactams. Isolates 
were additionally non-susceptible to cipro-
floxacin, erythromycin, gentamicin and tetra-
cycline (37.2%, 16/43); ciprofloxacin, gentamicin 
and tetracycline (16.3%, 7/43); ciprofloxacin, 
erythromycin and gentamicin (11.6%, 5/43); 
ciprofloxacin, erythromycin and tetracycline 
(9.3%, 4/43); ciprofloxacin (7.0% 3/43); cipro-
floxacin and erythromycin (4.7%, 2/43). Single 
isolates were resistant to either ciprofloxacin 
and gentamicin; ciprofloxacin and rifampicin; 
ciprofloxacin and tetracycline; ciprofloxacin, 
tetracycline and fusidic acid; ciprofloxacin, 
erythromycin, tetracycline and co-trimoxazole; 
or ciprofloxacin, erythromycin, tetracycline and 
high-level mupirocin. Overall 61.4% of ST45-VT 
were community-onset.
ST5-IV accounted for 11.3% of CA-MRSA and 
was isolated in all regions of Australia except the 
Australian Capital Territory ranging from 0% to 
18.1% in Queensland (Table 5). ST5-IV, of which 
23% were PVL positive, was typically resistant 
to the β-lactams only 43.6% (17/39); to β-lactams 
and co-trimoxazole (30.8%, 12/39); or addition-
ally resistant to either erythromycin; fusidic 
acid; high-level mupirocin; or gentamicin and 
high-level mupirocin. Overall 66.7% of ST5-IV 
were community-onset.
ST1-IV accounted for 9.9% of CA-MRSA rang-
ing from 1.4% in New South Wales to 100% in 
Tasmania (Table 5). Typically PVL negative, 
48.4% of isolates were resistant to the β-lactams 
only (15/31) or additionally resistant to eryth-
romycin (25.8%, 8/31); fusidic acid (9.7%, 3/31); 
erythromycin and fusidic acid (6.5%, 2/31). 
Single isolates were resistant to either cipro-
floxacin; erythromycin and tetracycline; or 
gentamicin and high-level mupirocin. Overall 
76.5% of ST1-IV were community-onset.
ST78-IV accounted for 4.7% of CA-MRSA and 
was predominantly isolated in Western Australia 
(Table 5). Isolates were resistant to the β-lactams 
and erythromycin (87.5%, 14/16); one isolate 
resistant to the β-lactams only; and one isolate 
additionally resistant to high-level mupirocin. 
Overall 81.3% of ST78-IV were community-
onset.
Overall 85.3% of CA-MRSA were non-multire-
sistant including 43.5% resistant to the β-lactams 
only. However 50 (14.7%) CA-MRSA isolates 
were multi-resistant, a significant increase from 
ASSOP 2016 (7.7%, p=0.01).17 Multi-resistance 
was primarily due to the ST45-VT clone.
Panton-Valentine leucocidin: Overall 171 
(37.0%) MRSA were PVL positive, including 
49.7% of CA-MRSA (Table 3).
Discussion
The AGAR surveillance programmes collect 
data on antimicrobial resistance, focussing on 
bloodstream infections caused by S. aureus, 
Enterococcus and Enterobacteriaceae. All data 
collected in the AGAR programs are generated 
as part of routine patient care in Australia, with 
most available through laboratory and hospital 
bed management information systems. Isolates 
are referred to a central laboratory where strain 
and antimicrobial resistance determinant char-
acterisation is performed. As the programmes 
are similar to those conducted in Europe,18 com-
parison of Australia antimicrobial resistance 
data with other countries is possible.
In ASSOP 2017, 19.0% (95% CI 17.5–20.6) of 
the 2,515 SAB episodes were methicillin resist-
ant. In the 2017 European Centre for Disease 
Prevention and Control and Prevention (ECDC) 
SAB surveillance program, the European 
Union/European Economic Area (EU/EEA) 
population-weighted mean percentage of S. 
aureus resistant to methicillin was 16.9% (95% 
CI 17–17), ranging from 1.0% (95% CI 1–2) in 
Norway to 44.4% (95% CI 40–49) in Romania.18
Europe has seen the EU/EEA population-
weighted mean percentage has significantly 
decreased from 23.2% in 2009 to 16.9% in 2017. 
The percentage of methicillin-resistant SAB in 
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Australia however has remained stable over the 
five years of ASSOP ranging from 19.1% in 2013 
to 19.0% in 2017.
A decrease in methicillin-resistant SAB is 
consistent has been reported in several parts 
of the world19,20 and is believed to be due to the 
implementation of antimicrobial stewardship 
and a package of improved infection control 
procedures including hand hygiene, MRSA 
screening and decolonisation, patient isolation 
and infection prevention care bundles.21–25 In 
Australia although we have not seen a decrease 
in MRSA bacteraemia we have observed sig-
nificant decreases in HA-MRSA from 41.0% to 
25.5% (p<0.001) and hospital-onset MRSA from 
38.0% to 29.9% (p=0.02) over the five ASSOP sur-
veys.11,17,26,27 Over the same time period we have 
observed a significant increase in CA-MRSA 
from 59.0% to 74.5% (p<0.001) and community-
onset MRSA from 61.1% to 70.1% (p=0.008).
Because of the increased burden of CA-MRSA 
bacteraemia in Australia a significant reduction 
in the overall proportion of SAB due to MRSA 
may prove problematic.
In ASSOP 2017 the all-cause mortality at 30-days 
was 14.8% (95% CI 13.3–16.4). In comparison, the 
2008 Australian New Zealand Cooperative on 
Outcomes in Staphylococcal Sepsis (ANZCOSS) 
reported a significantly higher figure of 20.6% 
(95% CI 18.8–22.5, p<0.001), and when adjusted 
for Australian institutions only was 25.9% 
(personal communication). MRSA-associated 
SAB mortality remains high (18.7%, 95% CI 
14.8–23.1) and was significantly higher than 
MSSA-associated SAB mortality (14.0%, 95% CI 
12.3–15.8), p=0.03.
With the exception of the β-lactams and eryth-
romycin, antimicrobial resistance in MSSA 
remains rare. However for MRSA in addition to 
the β-lactams, approximately 25% of isolates were 
resistant to erythromycin and ciprofloxacin and 
approximately 5% resistant to co-trimoxazole, 
tetracycline and gentamicin. Resistance was 
largely attributable to two healthcare-associated 
MRSA clones, ST22-IV [2B] (EMRSA-15), which 
is typically ciprofloxacin and erythromycin 
resistant, and ST239-III [3A] (Aus-2/3 EMRSA) 
which is typically erythromycin, clindamycin, 
ciprofloxacin, co-trimoxazole, tetracycline and 
gentamicin resistant. From the early 1980s until 
recently the multi-resistant ST239-III [3A] (Aus-
2/3 EMRSA) has been the dominant HA-MRSA 
clone in Australian hospitals. However, ST22-IV 
[2B] (EMRSA-15) has replaced ST239-III 
[3A] (Aus-2/3 EMRSA) as the most prevalent 
HA-MRSA isolated from clinical specimens 
and this change has occurred throughout most 
of the country.28 In ASSOP 2017 approximately 
20% of MRSA were characterised as ST22-IV 
[2B] (EMRSA-15). CA-MRSA, in particular the 
ST45-VT clone (9.5% of MRSA), has acquired 
multiple antimicrobial resistance determinants 
including ciprofloxacin, erythromycin, clinda-
mycin, gentamicin and tetracycline.
Resistance was not detected for vancomycin, 
linezolid or teicoplanin when CLSI interpretive 
criteria were applied. However five isolates were 
teicoplanin non-susceptible when EUCAST cri-
teria were applied. There were six isolates resist-
ant to daptomycin by both CLSI and EUCAST 
criteria.
Approximately 24.4% of SAB caused by 
CA-MRSA were healthcare-onset. Transmission 
of CA-MRSA in Australian hospitals is thought 
to be rare.29,30 It is likely that many of the health-
care onset CA-MRSA SAB infections reported 
in ASSOP 2017 were caused by the patient’s own 
colonising strains acquired prior to admission. 
In Australia CA-MRSA clones such as PVL-
positive ST93-IV [2B] (Queensland CA-MRSA) 
are well established in the community and 
therefore it is important to monitor antimicro-
bial resistance patterns in both community and 
healthcare-associated SAB as this information 
will guide therapeutic practices in treating S. 
aureus sepsis.
In conclusion, ASSOP 2017 has demonstrated 
antimicrobial resistance in SAB in Australia 
continues to be a significant problem and con-
tinues to be associated with a high mortality. 
This may be due, in part, to the high prevalence 
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of methicillin-resistant SAB in Australia, which 
is significantly higher than most EU/EEA coun-
tries. Consequently MRSA must remain a public 
health priority and continuous surveillance of 
SAB and its outcomes and the implementation of 
comprehensive MRSA strategies targeting hos-
pitals and long-term care facilities are essential.
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